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Dear editor
I read, with great interest, the paper on the intraocular pressure-lowering properties 
of intravenous paracetamol (acetaminophen) recently published in this journal by 
van den Heever and Meyer.1 The authors documented a decrease from baseline in 
mean intraocular pressure of 15.7% in a 6-hour time interval following intravenous 
paracetamol (1 g Perfalgan®, Bristol-Myers Squibb, New York, NY, USA) administra-
tion. This mean decrease was moderate but relevant when compared to, for example, 
topical timolol (-25.3%, single drop 0.5% timolol maleate) or oral acetazolamide 
(-23.1%, 250 mg). Although the authors provided potential relevant mechanistic 
arguments in support of a link between paracetamol administration and intraocular 
pressure through the endocannabinoid system, we would like to draw attention to 
the fact that – when intravenous paracetamol is administered – a relevant amount of 
mannitol is coadministered.
Clinicians and clinical researchers should be aware that drug formulations 
commonly contain excipient(s) besides the active compound(s). This is also true for 
Perfalgan® that contains ~3.9 g of mannitol (in 1 g paracetamol in a 100 mL vial).2 
I suggest that at least part of the effects observed may relate to the excipient, mannitol. 
Although recommendations do vary, mannitol doses of 0.25–2 g/kg over 30–60 minutes 
have been suggested to reduce intraocular pressure; while the paracetamol formulation 
results in coadministration of mannitol (3.9 g =0.055 g/kg over 15 minutes). To further 
illustrate this, 12 g of intravenous mannitol resulted in a drop in intraocular pressures 
with a subsequent return to baseline by 2 hours in 38 eyes of 19 subjects.3
Understanding the mechanism(s) involved in the reduction in intraocular pressure 
matters and goes beyond academic reflections. First, not all currently marketed 
intravenous paracetamol formulations contain mannitol.2 This means that the clinical 
message of the paper to consider recent exposure to intravenous paracetamol when 
interpreting ocular pressure measurement should be considered carefully until the 
mannitol effect has been disentangled from the paracetamol effect. Similarly, initiating 
acute or chronic exposure to paracetamol (either systemic through intravenous or oral, 
or topical) necessitates additional observations, adding another group exposed to similar 
amount of intravenous mannitol or comparing two paracetamol formulations containing 
one containing mannitol, the other without mannitol: “mannitol may matter.”
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Dear editor
We appreciate the comments received in response to our 
paper correctly highlighting the fact that not all intravenous 
paracetamol formulations contain the same excipients and 
that intravenous paracetamol has also manifested other unin-
tended systemic side effects. An example of this is apparent 
systemic hypotension.1,2 Whether these unintended effects 
result from pharmacological (drug or excipients) or nonphar-
macological (volume addition or excipients) factors is not 
yet clear. Further studies comparing different formulations of 
intravenous paracetamol will assist in quantifying the relative 
contribution of the following components of intravenous 
paracetamol to possible change in intraocular pressure (IOP): 
rapid addition of intravascular volume, paracetamol as a drug, 
and the excipients in the solution.2–4
Given the known inconsistency of the dose–response 
curve of mannitol, purely theoretical prediction of any ocular 
hypotensive effect at the quantities contained in Perfalgan® 
(3.85 g and 300 mOsmol/kg) would probably not be helpful 
without clinical testing.5 This should form the primary objec-
tive in a follow-up study.
What we do know is that paracetamol has IOP-lowering 
properties and numerous papers show that paracetamol 
interacts with the endocannabinoid system.6–9 Unpublished 
data from our laboratory show that topical paracetamol has 
IOP-lowering properties in New Zealand White rabbits.
The aim of our study however was to attempt to answer 
the following question in clinical ophthalmology: Is 
there a change in IOP after intravenous administration of 
paracetamol (in our case, Perfalgan®)? Although an ocular 
hypotensive effect might support the endocannabinoid mech-
anism of action of paracetamol claimed by Högestätt et al9 
and Ottani et al,8 this was not the conclusion of our study. 
Our findings could only conclude that clinicians interpret IOP 
measurements taken within 6 hours after the administration 
of intravenous paracetamol with caution.
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